Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | CCKBR | P32239 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | CCKAR | P32238 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170507 | 1.00 | SCN9A (0.45) | SCN9ACCKBRMEN1KMT2AF2 | |
| SCHEMBL4267961 | 0.90 | SCN9A (0.46) | SCN9ACCKBRMEN1KMT2AF2 | |
| SCHEMBL4108691 | 0.90 | SCN9A (0.46) | SCN9ACCKBRMEN1KMT2AF2 | |
| SCHEMBL4162902 | 0.88 | SCN9A (0.45) | SCN9ACCKBRMEN1KMT2AF2 | |
| SCHEMBL4265005 | 0.88 | SCN9A (0.45) | SCN9ACCKBRMEN1KMT2AF2 | |
| SCHEMBL4269095 | 0.88 | CCKBR (0.46) | SCN9ACCKBRMEN1KMT2AF2 | |
| SCHEMBL4117214 | 0.88 | CCKBR (0.46) | SCN9ACCKBRMEN1KMT2AF2 | |
| SCHEMBL4107821 | 0.88 | CTSL (0.45) | SCN9ACCKBRCCKAR | |
| SCHEMBL4166403 | 0.88 | CTSL (0.45) | SCN9ACCKBRCCKAR | |
| SCHEMBL4106136 | 0.86 | SCN9A (0.47) | SCN9ACCKBRMEN1KMT2AF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149504-A1 | Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| EP-1912706-A4 | NOVEL 5-SUBSTITUTED INDOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV (DPP-IV) INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIE (IN) | 2009-05-27 | — | — | EP | disclosed |
| EP-1912706-A2 | NOVEL 5-SUBSTITUTED INDOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV (DPP-IV) INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2008-04-23 | — | — | EP | disclosed |
| WO-2006134613-A2 | NOVEL 5-SUBSTITUTED INDOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV (DPP-IV) INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149504-A1 | Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors | DPP4, DPP3, DPP7 | SCN9A 1961/4885CCKBR 1192/4885MEN1 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.